Mundipharma and Vectura announce plans to reformulate flutiform® (fluticasone propionate/formoterol fumarate) pressurised metered-dose inhaler (pMDI) as a commitment to reducing the product’s carbon footprint

Contributed by: Business Wire

Logo

Tags

Biotechnology

General Health

Other Health

Health

Pharmaceutical

flutiform

More Like This

Trixeo Aerosphere approved in the UK as first inhaled respiratory medicine using next-generation propellant with near-zero Global Warming Potential

Kindeva Drug Delivery Invests in Second Manufacturing Line for Greener Inhalers at UK Manufacturing Site

Vectura Fertin Pharma, Inc., a Subsidiary of Philip Morris International, Announces Agreement for Sale of Vectura Group to Molex

Orbia Fluor & Energy Materials Advances Project to Increase Production of Zephex® 152a in UK

Kindeva Drug Delivery and Orbia Fluorinated Solutions (Koura) Announce Collaboration for Low GWP Propellant Conversion

Ferrer Obtains the Distribution Rights for Treprostinil Inhalation Solution Including the Potential Indications for Idiopathic Pulmonary Fibrosis (IPF) and Progressive Pulmonary Fibrosis (PPF)

Phillips Medisize Announces Scientific Presentations and Engagements at Respiratory Drug Delivery Conference, Highlighting Its Expanded Inhalation Drug Delivery Capabilities

Phillips Medisize Expands Its Inhalation Drug Delivery Capabilities